UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Pursuant~~Date toof ~~Section 13~~Report ~~or 15~~(d)Date of ~~the~~earliest ~~Securities~~event ~~Exchange~~reported): September ~~Act~~14, ~~of 1934~~2016

~~Date~~BSD ofMEDICAL ~~Report~~CORPORATION (~~Date~~Exact name of ~~earliest~~registrant ~~event~~as ~~reported):~~specified ~~September~~in 8,its ~~2016~~charter)

BSD Medical Corporation

(Exact name of registrant as specified in its charter)

Delaware	001-32526	75-1590407
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1969 Claremont Dr.

Bountiful, Utah 84010 (Address of principal executive offices, including Zip Code)

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (801) 725-4625

~~391~~N/A ~~Chipeta~~(Former ~~Way~~name or former address, ~~Suite~~if Fchanged since last report)

Salt Lake City, Utah 84108

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 57.0201 Regulation ~~Departure~~FD ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Disclosure.

AsModified ~~reported~~SEC previously, on May 23, 2016, BSD Medical Corporation formerly known as Perseon Corporation (the “Company”) filed a voluntary petition for relief under chapter 11 of 11 U.S.C. §§ 101 et seq. of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Utah (the “Bankruptcy Court”). The Company’s caption and case number is In re BSD Medical Corporation, fka Perseon Corporation, Case No. 16-24435 (Bankr. D. Utah) (the “Chapter 11 Case”). The Company continues to operate its business as a “debtor-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court.Reporting

InAs ~~addition,~~reported ~~as disclosed~~ previously, on ~~August~~May 2223, 2016, BSD Medical Corporation f/k/a Perseon Corporation (the “Company”) ~~sold~~filed ~~substantially~~a ~~all~~voluntary petition for relief under Chapter 11 of ~~the~~11 ~~assets~~U.S.C. §§ 101 et seq. of the ~~Company~~United States Code (the “~~Asset~~Bankruptcy ~~Sale~~Code”). toThe ~~Scion~~matter is styled as In re BSD Medical ~~Technologies~~Corporation, ~~LLC~~fka Perseon Corporation, Case No. ~~Following~~16-24435 (Bankr. D. Utah) (the ~~closing~~“Chapter of11 Case”) in the ~~Asset~~United ~~Sale,~~States Bankruptcy Court for the ~~Company~~District isof ~~focusing~~Utah ~~its~~(the ~~efforts~~“Bankruptcy onCourt”). The ~~liquidating~~Company continues to operate its ~~remaining~~business ~~assets~~as ~~and~~a ~~developing~~“debtor-in-possession” ~~and~~under ~~seeking~~the jurisdiction of the Bankruptcy Court ~~approval~~and in accordance with applicable provisions of athe ~~chapter~~Bankruptcy 11Code ~~plan~~and orders of the Bankruptcy Court.

~~Departure~~During the pendency of ~~Clinton~~the EChapter 11 Case, the Company has adopted a modified reporting program with respect to its reporting obligations under federal securities laws. ~~Carnell~~In Jrlieu of filing annual reports on Form 10-K and quarterly reports on Form 10-Q, each month the Company will file with the Securities and Exchange Commission (the “SEC”) a current report on Form 8-K that will have attached to it the monthly operating report required by the Bankruptcy Court. The Company does not intend to file periodic reports while the Chapter 11 Case is pending, but will continue to file current reports on Form 8-K as ~~President~~required ~~and~~by ~~Chief~~federal ~~Executive~~securities ~~Officer~~laws. The Company believes that this modified reporting program is consistent with the protection of its investors as set forth in Exchange Act Release No. 9660, dated June 30, 1972.

InOperating an effort to reduce administrative expenses, the Board of Directors of the Company decided it is in the best interest of the Company’s creditors and the bankruptcy estate to terminate the employment of Clinton E. Carnell Jr. as President and Chief Executive Officer of the Company as of September 8, 2016, and the Company has filed a motion with the Bankruptcy Court to reject Mr. Carnell’s employment agreement.Report

~~Appointment~~On ofSeptember ~~Timothy~~14, C2016, the Company filed a monthly operating report with the Bankruptcy Court that presides over the Chapter 11 Case for the period that began on August 1, 2016 and ended on August 31, 2016 (the “Operating Report”). ~~McQuay~~The Operating Report is attached hereto as ~~President~~Exhibit 99.1 and is incorporated herein by reference.

OnThe ~~September~~Operating 8,Report ~~2016,~~is ~~Timothy~~furnished C.for ~~McQuay,~~informational ~~chairman~~purposes only and shall not be deemed “filed” for purposes of ~~the~~Section ~~Board~~18 of ~~Directors~~the Securities Exchange Act of 1934, as amended (the ~~Company~~“Exchange Act”), ~~was~~or ~~appointed~~otherwise ~~President~~subject ofto the ~~Company.~~liabilities Noof ~~determination~~that ~~has~~section, ~~been~~nor ~~made~~will bysuch ~~the~~information ~~Board~~be ofdeemed ~~Directors~~incorporated asby toreference in any ~~compensation~~filing ~~for~~under ~~his~~the ~~service~~Exchange asAct ~~President~~or of the ~~Company.~~Securities InAct ~~addition~~of 1933, ~~neither~~as ~~Mr.~~amended, ~~McQuay~~except ~~nor~~as ~~any~~expressly ~~other~~set ~~member~~forth ofby ~~the~~specific ~~Board~~reference ofin ~~Directors~~such ofa ~~the~~filing. ~~Company~~This ~~has~~Current ~~received~~Report ~~any~~on ~~compensation,~~Form 8-K (including ~~equity~~the ~~and~~exhibit ~~stock-based~~hereto) ~~compensation,~~should ~~since~~not be deemed an admission as to the ~~filing~~materiality of ~~the~~any ~~Chapter~~information 11required ~~Case~~to be disclosed solely by Regulation FD.

~~Mr.~~Cautionary ~~McQuay,~~Note ~~64,~~Regarding ~~has served on~~ the ~~Board~~Operating of Directors of the Company since February 1, 2008. He retired from his position as Managing Director – Investment Banking with Noble Financial Capital Markets on December 31, 2015. Prior to joining Noble Financial Capital Markets in November 2011, Mr. McQuay was a Managing Director – Investment Banking with B. Riley & Co. Prior to joining B. Riley & Co. in September 2008, Mr. McQuay served for ten years as Managing Director – Investment Banking with A. G. Edwards & Sons, Inc., where he specialized in Healthcare, including medical technology, biotechnology and specialty pharmaceuticals. He currently serves as a member of the Board of Directors of Superior Industries International, Inc. Mr. McQuay holds an AB in Economics from Princeton University and an MBA from UCLA.Report

~~-2-~~The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Operating Report, which report was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The Operating Report is limited in scope, covers a limited time period, has been prepared solely for the purpose of complying with the requirements applicable in the Chapter 11 Case and is in a format acceptable to the U.S. Trustee. The financial information contained in the Operating Report was not audited or reviewed by independent public accountants, does not contain all of the information and footnotes required by generally accepted accounting principles in the United States, are in a format prescribed by applicable bankruptcy laws, and are subject to future adjustment and reconciliation. There can be no assurance that, from the perspective of an investor or potential investor in the Company's securities, the financial information contained in the Operating Report is complete. The Operating Report also contains information for periods which are shorter or otherwise different from those required in the

Company's reports pursuant to the Exchange Act, and such information might not be indicative of the Company's financial condition or operating results for the period that would be reflected in the Company's financial statements or in its reports pursuant to the Exchange Act. Results set forth in the Operating Report should not be viewed as indicative of future results.

Cautionary Note Regarding Forward-Looking Statements

Certain statements and information included herein may constitute “forward-looking” statements that are generally identifiable through the use of words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “project” and similar expressions and include any statements that are made regarding earnings expectations. The forward-looking statements speak only as of the date of this report, and the Company undertakes no obligation to update or revise such statements to reflect new information or events as they occur. These statements are based on a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Investors are cautioned that any such statements are not guarantees of future performance and that actual future results may differ materially due to a variety of factors. Factors that could cause the Company's results to differ materially include: (i) the Company's ability to obtain Bankruptcy Court approval with respect to motions in the Chapter 11 Case; (ii) the Company's ability to operate its business during this process, (iii) the effects of the Company's bankruptcy filing on the Company's business and the interests of various creditors, equity holders and other constituents, (iv) the length of time the Company will operate under the Chapter 11 Case, (v) risks associated with third-party motions in the Chapter 11 Case, which may interfere with the Company's ability to develop and consummate a plan of reorganization, (vi) the potential adverse effects of the Chapter 11 Case on the Company's liquidity or results of operations, and (vii) other factors disclosed by the Company from time to time in its filings with the SEC, including those described under the caption “Risk Factors” in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. As a result of these factors, the Company's actual results may differ materially from those indicated or implied by such forward-looking statements.

Cautionary Note Regarding Chapter 11 Case

The Company's stockholders are cautioned that trading in the Company's equity securities, including its common stock and publicly traded warrants, during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. Trading prices for the Company's equity securities may bear little or no relationship to the actual recovery, if any, by holders of the Company's equity upon wind-up of the Chapter 11 Case. Accordingly, the Company urges extreme caution with respect to existing and future investments in its equity securities.

Except as required by law, the Company disclaims any obligation to publicly update such statements.

~~-3-~~Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Operating Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BSD MEDICAL CORPORATION
Date: September 13, 2016	By:	/s/ Timothy C. McQuay
	Name:	Timothy C. McQuay
	Title:	President

BSD MEDICAL CORPORATION

~~-4-~~Date: October 13, 2016

By: /s/ Timothy C. McQuay

Name: Timothy C. McQuay

Title: President

EXHIBIT INDEX

Exhibit Number		Description
99.1		Operating Report.

Filing Compare · BSD Medical Corp